Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, 40138 Bologna, Italy.
Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40138 Bologna, Italy.
Int J Mol Sci. 2021 Nov 5;22(21):12012. doi: 10.3390/ijms222112012.
Notch signaling has been identified as a critical regulator of cartilage development and homeostasis. Its pivotal role was established by both several joint specific Notch signaling loss of function mouse models and transient or sustained overexpression. NOTCH1 is the most abundantly expressed NOTCH receptors in normal cartilage and its expression increases in osteoarthritis (OA), when chondrocytes exit from their healthy "maturation arrested state" and resume their natural route of proliferation, hypertrophy, and terminal differentiation. The latter are hallmarks of OA that are easily evaluated in vitro in 2-D or 3-D culture models. The aim of our study was to investigate the effect of NOTCH1 knockdown on proliferation (cell count and Picogreen mediated DNA quantification), cell cycle (flow cytometry), hypertrophy (gene and protein expression of key markers such as RUNX2 and MMP-13), and terminal differentiation (viability measured in 3-D cultures by luminescence assay) of human OA chondrocytes. NOTCH1 silencing of OA chondrocytes yielded a healthier phenotype in both 2-D (reduced proliferation) and 3-D with evidence of decreased hypertrophy (reduced expression of RUNX2 and MMP-13) and terminal differentiation (increased viability). This demonstrates that NOTCH1 is a convenient therapeutic target to attenuate OA progression.
Notch 信号通路已被确定为软骨发育和稳态的关键调节因子。几个关节特异性 Notch 信号通路功能丧失的小鼠模型以及瞬时或持续过表达均证实了其关键作用。NOTCH1 是正常软骨中表达最丰富的 NOTCH 受体,其表达在骨关节炎 (OA) 中增加,此时软骨细胞从健康的“成熟阻滞状态”退出,并恢复其增殖、肥大和终末分化的自然途径。后者是 OA 的标志,在 2-D 或 3-D 培养模型中很容易在体外评估。我们的研究目的是研究 NOTCH1 敲低对人 OA 软骨细胞增殖(细胞计数和 Picogreen 介导的 DNA 定量)、细胞周期(流式细胞术)、肥大(关键标志物如 RUNX2 和 MMP-13 的基因和蛋白表达)和终末分化(3-D 培养中的活力通过发光测定法测量)的影响。OA 软骨细胞中的 NOTCH1 沉默在 2-D(增殖减少)和 3-D 中均产生了更健康的表型,证据表明肥大减少(RUNX2 和 MMP-13 的表达减少)和终末分化(活力增加)。这表明 NOTCH1 是一种减轻 OA 进展的便利治疗靶点。